This article is more than 5 years old. Information may no longer be current.

EyePoint plans accelerated Dexycu launch

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyePoint Pharmaceuticals will launch both Dexycu and Yutiq in the first quarter, the company announced in a press release.

The two drugs were approved in 2018, and while the company originally planned to launch Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) in the first quarter of 2019 and Dexycu (dexamethasone intraocular suspension 9%) in the first half of the year, it has moved its timeline forward to launch both in the year’s first few months.

“EyePoint has made significant progress in building its commercial infrastructure in preparation for two ophthalmic product launches in the near term,” EyePoint President and CEO Nancy Lurker said in the release. “We are excited to be able to commercialize both of these innovative ocular products, and we look forward to making a meaningful difference in the established treatment paradigms for cataract surgery and posterior uveitis, which are both areas of high unmet medical need.”